I have relatives who died by cancer, which is why I like to invest in biotech companies who research and develop cancer treatment. First, I bought $KNTE 20k shares @ $2.53, but this company was merged by $XOMA and off public. They refunded the amount of cash equal that I spent plus CVR, not bad at all. Second, after a long time watching, I finally bought $PMVP 3k shares @ $0.90 and $XLO 4k shares @ $0.67. Both companies have mc up to around $50M and phase 2 clinic trials, but cash on hand is bigger, mc. $PMVP is $185M, while $XLO is $85M. Hope they can safely exit Death Valley. Third, $MAIA data phase 2 looks promised, but cash is too few, around $10M. Keep watching.
$KNTE Kinnate Biopharma Inc. (NASDAQ:KNTE): Navigating the Complexities of Precision Oncology https://beyondspx.com/article/kinnate-biopharma-inc-nasdaq-knte-navigating-the-complexities-of-precision-oncology
$KNTE Kinnate Biopharma Inc. (NASDAQ:KNTE): Navigating the Complexities of Precision Oncology http://beyondspx.com/2024/08/05/kinnate-biopharma-inc-nasdaqknte-navigating-the-complexities-of-precision-oncology/
$XOMA $KNTE Xoma announces closing of tender offer 09:14
XOMA Corporation announced the Company has completed its previously announced tender offer to acquire all outstanding shares of Kinnate Biopharma common stock for a price per share of $2.5879 in cash, plus one non-tradeable contingent value right representing the right to receive 85% of the net proceeds from any out license or sale of Kinnate programs effected within one year of closing of the merger and 100% of the net proceeds resulting from Kinnate's sale of exarafenib and other pan-RAF program assets to Pierre Fabre Laboratories, as announced on March 1, 2024. The tender offer and related withdrawal rights expired one minute after 11:59 p.m. Eastern Time on Tuesday, April 2, 2024. As of the Expiration Date, a total of 38,258,681 shares of Kinnate common stock were validly tendered, and not validly withdrawn, representing approximately 81% of the outstanding shares of Kinnate common stock as of the Expiration Date....
$KNTE Kinnate's sale of oncology assets to Pierre Fabre for up to $31M plus costs represents a strategic refocus. Shareholders, this move promises future financial returns tied to milestones and sharpens our core mission. Optimism is warranted as we advance. Patience and focus will guide us through this promising transition. They must know something w don’t know…. Yet. #KNTE now Neutral.
$KNTE this may be a stupid question but why would anyone be buying this over the $2.58 max buyout price? The CVR based on today’s news? This scenario is new to me. Thanks.
$KNTE Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories
https://www.stocktitan.net/news/KNTE/kinnate-biopharma-inc-sells-its-investigational-pan-raf-inhibitor-vegj5eyb4ipl.html
$KRON XOMA just bought $KNTE for about $2.50/share. KNTE comparable to KRON but KRON has more $$. By compariso this transaction should make $KRON value minimum of $3.50/share
$XOMA to acquire Kinnate Biopharma ($KNTE) for between $2.3352 and $2.5879 in cash per share plus a contingent value right https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240216080337KNTE&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
